This company has been acquired
DURECT (DRRX) Stock Overview
A biopharmaceutical company, develops medicines based on its epigenetic regulator program. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 2 more risks
DRRX Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
DURECT Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.91 |
| 52 Week High | US$2.64 |
| 52 Week Low | US$0.48 |
| Beta | 0.93 |
| 1 Month Change | 2.14% |
| 3 Month Change | 198.44% |
| 1 Year Change | 21.66% |
| 3 Year Change | -68.69% |
| 5 Year Change | -89.21% |
| Change since IPO | -98.67% |
Recent News & Updates
Recent updates
Brokers Are Upgrading Their Views On DURECT Corporation (NASDAQ:DRRX) With These New Forecasts
Aug 08
Durect names ex-RBC Capital Markets executive as CFO
Jul 05Is DURECT (NASDAQ:DRRX) A Risky Investment?
May 12DURECT Corporation (NASDAQ:DRRX) Analysts Are More Bearish Than They Used To Be
Mar 14DURECT Corporation (NASDAQ:DRRX) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
Mar 10Does DURECT (NASDAQ:DRRX) Have A Healthy Balance Sheet?
Jan 08Is DURECT (NASDAQ:DRRX) Using Debt Sensibly?
Aug 05Shareholder Returns
| DRRX | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -1.5% | 2.8% | -0.6% |
| 1Y | 21.7% | 25.1% | 15.5% |
Return vs Industry: DRRX exceeded the US Pharmaceuticals industry which returned -10.6% over the past year.
Return vs Market: DRRX exceeded the US Market which returned 20% over the past year.
Price Volatility
| DRRX volatility | |
|---|---|
| DRRX Average Weekly Movement | 68.1% |
| Pharmaceuticals Industry Average Movement | 9.6% |
| Market Average Movement | 6.6% |
| 10% most volatile stocks in US Market | 16.0% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: DRRX's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: DRRX's weekly volatility has increased from 36% to 68% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1998 | 13 | Jim Brown | www.durect.com |
DURECT Corporation, a biopharmaceutical company, develops medicines based on its epigenetic regulator program. The company’s lead product candidate includes larsucosterol, an endogenous, orally bioavailable small molecule to play a regulatory role in lipid metabolism, stress and inflammatory responses, and cell death and survival to treat alcohol-associated hepatitis, as well as for the treatment of patients with metabolic dysfunction-associated steatohepatitis. The company also offers POSIMIR, a post-surgical pain product to deliver bupivacaine over three days in adults; PERSERIS, an injectable suspension for the treatment of schizophrenia in adults; and Methydur to treat attention deficit hyperactivity disorder.
DURECT Corporation Fundamentals Summary
| DRRX fundamental statistics | |
|---|---|
| Market cap | US$59.93m |
| Earnings (TTM) | -US$13.09m |
| Revenue (TTM) | US$1.66m |
Is DRRX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| DRRX income statement (TTM) | |
|---|---|
| Revenue | US$1.66m |
| Cost of Revenue | -US$2.50m |
| Gross Profit | US$4.16m |
| Other Expenses | US$17.26m |
| Earnings | -US$13.09m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.42 |
| Gross Margin | 251.12% |
| Net Profit Margin | -790.28% |
| Debt/Equity Ratio | 0% |
How did DRRX perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/09/10 07:38 |
| End of Day Share Price | 2025/09/10 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
DURECT Corporation is covered by 8 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Mayank Mamtani | B. Riley Securities, Inc. |
| François Brisebois | Craig-Hallum Capital Group LLC |
| David Windley | Jefferies LLC |